Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates-Reference-Cited by-同舟云学术

Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates

Published:2022-12 Issue: Volume:319 Page:388-396
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Brendle Madeline,Robison Reid,Malone Daniel C.

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference36 articles.

1. The effectiveness and value of esketamine for the management of treatment-resistant depression;Agboola;J. Manag. Care Spec. Pharm.,2020

2. Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database;Amos;J. Clin. Psychiatry,2018

3. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines;Anderson;J. Am. Coll. Cardiol.,2014

4. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis;Bahji;J. Affect. Disord.,2021

5. Consumer Price Index, Calendar Year Historical, 2016-2020;BLS,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression;Psychiatry Research;2024-10

2. At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data;Journal of Affective Disorders;2024-09

3. Patient-Informed Value Elements in Cost-Effectiveness Analyses of Major Depressive Disorder Treatment: A Literature Review and Synthesis;Value in Health;2024-06

4. Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans;Journal of Psychiatric Practice;2024-03

5. Ketamine and Nitrous Oxide;Reference Module in Neuroscience and Biobehavioral Psychology;2024